Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Profound Medical (PROF) Common Equity (2023 - 2025)

Profound Medical has reported Common Equity over the past 3 years, most recently at $66.4 million for Q4 2025.

  • Quarterly results put Common Equity at $66.4 million for Q4 2025, up 9.95% from a year ago — trailing twelve months through Dec 2025 was $66.4 million (up 9.95% YoY), and the annual figure for FY2025 was $66.4 million, up 9.95%.
  • Common Equity for Q4 2025 was $66.4 million at Profound Medical, up from $32.1 million in the prior quarter.
  • Over the last five years, Common Equity for PROF hit a ceiling of $66.4 million in Q4 2025 and a floor of $30.7 million in Q3 2024.
  • Median Common Equity over the past 3 years was $39.3 million (2025), compared with a mean of $43.9 million.
  • Biggest five-year swings in Common Equity: surged 93.51% in 2024 and later rose 0.94% in 2025.
  • Profound Medical's Common Equity stood at $31.2 million in 2023, then surged by 93.51% to $60.4 million in 2024, then increased by 9.95% to $66.4 million in 2025.
  • The last three reported values for Common Equity were $66.4 million (Q4 2025), $32.1 million (Q3 2025), and $39.3 million (Q2 2025) per Business Quant data.